Published Date: 06 Jan 2025
Studies show promising EFS, PFS, and OS at 3 to 8 years
Read Full NewsPatients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers ...
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.
1.
Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness
2.
Cancerous breast tissue glows in new AI-enhanced MRI images
3.
Scholastic performance is a key concern for young cancer patients, study finds
4.
A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.
5.
Researchers identify a novel biomarker linked to renal cancer recurrence
1.
Everything You Need to Know About Normal Potassium Levels
2.
Liquid Biopsies and ctDNA: Transforming Cancer Detection, Monitoring, and Clinical Decisions
3.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
4.
Recombinant ADAMTS13: Advancing Prophylaxis in Congenital TTP Management
5.
The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation